(EKTA-B) Elekta (publ) - Ratings and Ratios
Radiotherapy, Stereotactic Surgery, Brachytherapy, Neurosurgery, Oncology
EKTA-B EPS (Earnings per Share)
EKTA-B Revenue
Description: EKTA-B Elekta (publ)
Elekta AB (publ) is a medical technology company specializing in clinical solutions for cancer and brain disorders. The company offers a comprehensive range of radiation therapy, stereotactic radiosurgery, brachytherapy, and neurosurgery products, as well as software solutions for treatment planning and management.
Key products include Elekta Unity, Versa HD, and Harmony, which cater to various radiotherapy needs, while Leksell Gamma Knife Icon and Perfexion are designed for radiosurgery. The companys brachytherapy offerings, such as Elekta Studio and Oncentra Brachy, facilitate precise treatment delivery. Additionally, Elekta provides neurosurgery products like Leksell Vantage Stereotactic System and personalized cancer care solutions through Elekta Kaiku.
From a financial perspective, Elektas market capitalization stands at approximately 18.4 billion SEK. The companys return on equity (ROE) is relatively low at 2.33%, indicating potential for improvement in profitability. The forward price-to-earnings (P/E) ratio is around 12.92, suggesting a more reasonable valuation compared to the current P/E of 77.52.
To further evaluate Elektas performance, key performance indicators (KPIs) such as revenue growth, gross margin, and research and development (R&D) expenditure as a percentage of revenue can be analyzed. For instance, a high R&D spend can indicate a strong commitment to innovation, while a stable gross margin can suggest effective cost management. Other relevant KPIs may include the companys order backlog, customer satisfaction ratings, and market share in the radiation therapy and neurosurgery segments.
Overall, Elektas diverse product portfolio and commitment to innovation position the company for potential growth in the medical technology sector. A thorough analysis of the companys financials, KPIs, and industry trends is necessary to determine its investment potential.
EKTA-B Stock Overview
| Market Cap in USD | 1,927m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception |
EKTA-B Stock Ratings
| Growth Rating | -49.9% |
| Fundamental | 48.6% |
| Dividend Rating | 68.3% |
| Return 12m vs S&P 500 | -32.3% |
| Analyst Rating | - |
EKTA-B Dividends
| Dividend Yield 12m | 6.83% |
| Yield on Cost 5y | 3.47% |
| Annual Growth 5y | 5.92% |
| Payout Consistency | 90.4% |
| Payout Ratio | 80.3% |
EKTA-B Growth Ratios
| Growth Correlation 3m | -28.3% |
| Growth Correlation 12m | -89.3% |
| Growth Correlation 5y | -72.8% |
| CAGR 5y | -1.12% |
| CAGR/Max DD 3y | -0.02 |
| CAGR/Mean DD 3y | -0.08 |
| Sharpe Ratio 12m | 1.11 |
| Alpha | -31.04 |
| Beta | 0.473 |
| Volatility | 29.48% |
| Current Volume | 2256.7k |
| Average Volume 20d | 1048k |
| Stop Loss | 47.9 (-3.7%) |
| Signal | 0.83 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (274.0m TTM) > 0 and > 6% of Revenue (6% = 1.07b TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA 2.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 3.88% (prev -0.68%; Δ 4.56pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 3.03b > Net Income 274.0m (YES >=105%, WARN >=100%) |
| Net Debt (4.98b) to EBITDA (2.18b) ratio: 2.28 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.05 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (382.0m) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 37.40% (prev 36.45%; Δ 0.95pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 58.90% (prev 57.67%; Δ 1.24pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.21 (EBITDA TTM 2.18b / Interest Expense TTM 400.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.51
| (A) 0.02 = (Total Current Assets 13.44b - Total Current Liabilities 12.75b) / Total Assets 29.15b |
| (B) 0.23 = Retained Earnings (Balance) 6.64b / Total Assets 29.15b |
| (C) 0.03 = EBIT TTM 885.0m / Avg Total Assets 30.28b |
| (D) 0.40 = Book Value of Equity 7.99b / Total Liabilities 20.02b |
| Total Rating: 1.51 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 48.56
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 7.18% = 3.59 |
| 3. FCF Margin 8.89% = 2.22 |
| 4. Debt/Equity 0.75 = 2.23 |
| 5. Debt/Ebitda 3.13 = -1.93 |
| 6. ROIC - WACC -3.23% = -4.04 |
| 7. RoE 2.80% = 0.23 |
| 8. Rev. Trend -2.14% = -0.11 |
| 9. Rev. CAGR -4.02% = -0.67 |
| 10. EPS Trend -24.46% = -0.61 |
| 11. EPS CAGR -18.82% = -2.35 |
What is the price of EKTA-B shares?
Over the past week, the price has changed by +12.28%, over one month by +7.58%, over three months by +4.24% and over the past year by -19.45%.
Is Elekta (publ) a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EKTA-B is around 47.34 SEK . This means that EKTA-B is currently overvalued and has a potential downside of -4.83%.
Is EKTA-B a buy, sell or hold?
What are the forecasts/targets for the EKTA-B price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 53.8 | 8.1% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 51.5 | 3.5% |
EKTA-B Fundamental Data Overview
Market Cap SEK = 18.01b (18.01b SEK * 1.0 SEK.SEK)
CCE Cash And Equivalents = 2.76b SEK (Cash And Short Term Investments, last quarter)
P/E Trailing = 65.2222
P/E Forward = 12.4378
P/S = 1.0098
P/B = 1.963
P/EG = 1.2804
Beta = 1.005
Revenue TTM = 17.84b SEK
EBIT TTM = 885.0m SEK
EBITDA TTM = 2.18b SEK
Long Term Debt = 5.71b SEK (from longTermDebt, last quarter)
Short Term Debt = 1.10b SEK (from shortTermDebt, last quarter)
Debt = 6.81b SEK (Calculated: Short Term 1.10b + Long Term 5.71b)
Net Debt = 4.98b SEK (from netDebt column, last quarter)
Enterprise Value = 22.07b SEK (18.01b + Debt 6.81b - CCE 2.76b)
Interest Coverage Ratio = 2.21 (Ebit TTM 885.0m / Interest Expense TTM 400.0m)
FCF Yield = 7.18% (FCF TTM 1.58b / Enterprise Value 22.07b)
FCF Margin = 8.89% (FCF TTM 1.58b / Revenue TTM 17.84b)
Net Margin = 1.54% (Net Income TTM 274.0m / Revenue TTM 17.84b)
Gross Margin = 37.40% ((Revenue TTM 17.84b - Cost of Revenue TTM 11.17b) / Revenue TTM)
Tobins Q-Ratio = 2.76 (Enterprise Value 22.07b / Book Value Of Equity 7.99b)
Interest Expense / Debt = 1.22% (Interest Expense 83.0m / Debt 6.81b)
Taxrate = 51.02% (250.0m / 490.0m)
NOPAT = 433.5m (EBIT 885.0m * (1 - 51.02%))
Current Ratio = 1.05 (Total Current Assets 13.44b / Total Current Liabilities 12.75b)
Debt / Equity = 0.75 (Debt 6.81b / last Quarter total Stockholder Equity 9.09b)
Debt / EBITDA = 3.13 (Net Debt 4.98b / EBITDA 2.18b)
Debt / FCF = 4.30 (Debt 6.81b / FCF TTM 1.58b)
Total Stockholder Equity = 9.77b (last 4 quarters mean)
RoA = 0.94% (Net Income 274.0m, Total Assets 29.15b )
RoE = 2.80% (Net Income TTM 274.0m / Total Stockholder Equity 9.77b)
RoCE = 5.72% (Ebit 885.0m / (Equity 9.77b + L.T.Debt 5.71b))
RoIC = 2.56% (NOPAT 433.5m / Invested Capital 16.93b)
WACC = 5.79% (E(18.01b)/V(24.83b) * Re(7.76%)) + (D(6.81b)/V(24.83b) * Rd(1.22%) * (1-Tc(0.51)))
Shares Correlation 3-Years: -42.27 | Cagr: -0.00%
Discount Rate = 7.76% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 71.69% ; FCFE base≈1.28b ; Y1≈888.9m ; Y5≈454.0m
Fair Price DCF = 23.80 (DCF Value 8.77b / Shares Outstanding 368.6m; 5y FCF grow -35.88% → 3.0% )
Revenue Correlation: -2.14 | Revenue CAGR: -4.02%
Rev Growth-of-Growth: -6.61
EPS Correlation: -24.46 | EPS CAGR: -18.82%
EPS Growth-of-Growth: -23.28